The inhibition of TXNIP promotes endogenous cell mass and insulin production, thereby becoming an attractive new candidate drug target for diabetes (Shalev, 2014; Wondafrash et al., 2020). The gene discussed is TXNIP; the disease is diabetes mellitus.